Schreiber RD - Search Results

1

Cancer immunoediting: from immunosurveillance to tumor escape.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Dunn GP, et al. Among authors: schreiber rd. Nat Immunol. 2002 Nov;3(11):991-8. doi: 10.1038/ni1102-991. Nat Immunol. 2002. PMID: 12407406 Review.

2

Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

Dighe AS, Richards E, Old LJ, Schreiber RD. Dighe AS, et al. Among authors: schreiber rd. Immunity. 1994 Sep;1(6):447-56. doi: 10.1016/1074-7613(94)90087-6. Immunity. 1994. PMID: 7895156

3

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Kaplan DH, et al. Among authors: schreiber rd. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61. doi: 10.1073/pnas.95.13.7556. Proc Natl Acad Sci U S A. 1998. PMID: 9636188 Free PMC article.

4

Signaling and signaling dysfunction through the interferon gamma receptor.

Rodig S, Kaplan D, Shankaran V, Old L, Schreiber RD. Rodig S, et al. Among authors: schreiber rd. Eur Cytokine Netw. 1998 Sep;9(3 Suppl):49-53. Eur Cytokine Netw. 1998. PMID: 9831186 Review. No abstract available.

5

Eradication of established tumors by CD8+ T cell adoptive immunotherapy.

Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Hanson HL, et al. Among authors: schreiber rd. Immunity. 2000 Aug;13(2):265-76. doi: 10.1016/s1074-7613(00)00026-1. Immunity. 2000. PMID: 10981969 Free article.

6

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. Shankaran V, et al. Among authors: schreiber rd. Nature. 2001 Apr 26;410(6832):1107-11. doi: 10.1038/35074122. Nature. 2001. PMID: 11323675

7

The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Ikeda H, Old LJ, Schreiber RD. Ikeda H, et al. Among authors: schreiber rd. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109. doi: 10.1016/s1359-6101(01)00038-7. Cytokine Growth Factor Rev. 2002. PMID: 11900986 Review.

8

The three Es of cancer immunoediting.

Dunn GP, Old LJ, Schreiber RD. Dunn GP, et al. Among authors: schreiber rd. Annu Rev Immunol. 2004;22:329-60. doi: 10.1146/annurev.immunol.22.012703.104803. Annu Rev Immunol. 2004. PMID: 15032581 Free article. Review.

9

The immunobiology of cancer immunosurveillance and immunoediting.

Dunn GP, Old LJ, Schreiber RD. Dunn GP, et al. Among authors: schreiber rd. Immunity. 2004 Aug;21(2):137-48. doi: 10.1016/j.immuni.2004.07.017. Immunity. 2004. PMID: 15308095 Free article. Review.

10

Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells.

Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Sakaguchi S, Old LJ, Shiku H. Nishikawa H, et al. Among authors: schreiber rd. J Exp Med. 2005 Mar 7;201(5):681-6. doi: 10.1084/jem.20041959. J Exp Med. 2005. PMID: 15753203 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

316 results

Search Page

Filters